Breaks Categories: Stock Spotlights

WednesdayFeb 11, 2026 2:51 pm

BioMedNewsBreaks — LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Bringing First-in-Class Approach to Chemo and Immunotherapy

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is focused on enhancing established cancer therapies by targeting a fundamental biological pathway involved in tumor survival and resistance. “Rather than developing standalone treatments, LIXTE is advancing a first-in-class approach designed to increase the effectiveness of chemotherapy and immunotherapy across multiple cancer indications,” reads a recent article. “At the center of LIXTE’s strategy is protein phosphatase 2A, or PP2A, an enzyme that plays a critical role in regulating cell growth, DNA repair, and survival signaling. In many cancers, PP2A activity enables tumor cells to recover from the damage caused by treatment,…

Continue Reading

WednesdayJan 21, 2026 1:30 pm

BioMedNewsBreaks — Oncotelic Therapeutics Inc.’s (OTLC) Deciparticle(TM) Platform Expands Possibilities in Immunology and Oncology

Oncotelic Therapeutics (OTCQB: OTLC) is rapidly emerging in next-generation drug delivery, with a scalable nanotechnology platform that can transform the paradigms of immunology and oncology treatments. “Leveraging Sapu Nano, the company’s clinical-stage nanomedicine, it unveiled new data at the 2025 San Antonio Breast Cancer Symposium (‘SABCS’), highlighting that its Deciparticle(TM) platform can package even the toughest, water-resistant drugs into smaller, uniform nanoparticles that are small enough for effective and safe intravenous use,” reads a recent article. “The platform shows high-level compatibility across different therapeutic categories. All five main macrolide mTOR inhibitors, including temsirolimus, sirolimus, ridaforolimus, Everolimus (Afinitor(R)), and umirolimus, formed stable,…

Continue Reading

FridayJan 09, 2026 12:57 pm

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Reaches Enrollment Milestone in Phase 3 FLASH2 Trial for HyBryte(TM)

Soligenix (NASDAQ: SNGX) is a New Jersey-based biopharmaceutical company focused on developing products to treat rare diseases where there is an unmet medical need. The company recently received updated analysis from Zacks Small-Cap Research following its announcement that milestone enrollment had been reached in the ongoing confirmatory Phase 3 FLASH2 trial of HyBryte(TM). The study focuses on the treatment of cutaneous T-cell lymphoma, with the overall blinded response rate standing at 48% for patients who have completed treatment. “In the Nov. 20, 2025, research report published by Zacks Small-Cap Research, expert analysis indicated strong conviction about the 50-patient enrollment milestone and…

Continue Reading

FridayJan 09, 2026 12:23 pm

BioMedNewsBreaks — Oncotelic Therapeutics Inc. (OTLC) Advances Nanoparticle Drug Delivery, Prepares First-in-Human Study of IV Everolimus

Oncotelic Therapeutics (OTCQB: OTLC) is positioned at the heart of the evolving landscape of pharmaceutical innovation, applying ultra-small carrier technologies to elevate existing cancer therapies. “The company is pioneering how nanotechnology can enhance bioavailability, precision targeting and therapeutic performance of anticancer compounds,” reads a recent article. “The advantages of nanoparticle delivery in pharma are significant… The contemporary view holds that nanocarrier-enabled formulations may be as transformative for drug delivery as the advent of monoclonal antibodies was for biologics… Into this context, Oncotelic Therapeutics, which in its most recent news has advanced nanoparticle-based delivery strategies through its joint venture entity, involving its…

Continue Reading

WednesdayDec 17, 2025 2:00 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Ranks Second Worldwide in 12-Lead ECG Innovation

HeartBeam (NASDAQ: BEAT), a medical-technology company developing advanced electrocardiogram solutions, was featured in a recent article that discussed its recognition as a Global IP and Technology Leader in Portable Cardiac Diagnostics by PatentVest’s “Total Cardiac Intelligence” report. “The company ranked second worldwide in 12-lead ECG innovation among 243 firms analyzed, trailing only GE Healthcare. The recognition highlights HeartBeam’s growing influence in the next generation of cardiac monitoring technology,” reads the article. “HeartBeam’s ranking underscores the rapid maturation of the company’s proprietary synthesis-ECG system, which captures the heart’s electrical signals in three noncoplanar dimensions and synthesizes them into a 12-lead ECG. This unique…

Continue Reading

FridayNov 28, 2025 2:29 pm

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Advancing Heat-Stable Vaccine Platform with New Peer-Reviewed Data

Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company specializing in biodefense and rare disease vaccines. The company recently published a peer-reviewed summary of new scientific data demonstrating long-term high-temperature stability of its protein subunit vaccine platform designed for Ebola and Marburg-related viruses. An article discussing this reads, “Soligenix has been developing formulations intended to remain stable even when stored for extended periods at temperatures above 40°C, a capability that could transform global outbreak response readiness. The company’s publication, titled ‘Development of Thermostable Filovirus Vaccines Using Protein Subunit Technology,’ outlines preclinical data showing that the company’s filovirus vaccine antigens, formulated with its proprietary ThermoVax(R)…

Continue Reading

WednesdayNov 19, 2025 12:50 pm

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Poised in the Future of Cardiac Care with Breakthrough Technology

HeartBeam (NASDAQ: BEAT) is on the verge of transforming how atrial fibrillation (“AF”) is detected and managed with its cable-free ECG technology. A recent article discussing this reads, “HeartBeam has developed a credit card-sized device and proprietary synthesis software that can capture heart signals in three dimensions and convert them into a full synthesized 12-lead ECG. By bringing clinical -grade cardiac diagnostics into the hands of patients wherever they are, HeartBeam is positioning itself at the forefront of a revolution in heart health, one that could greatly impact lives, reduce costs, and redefine the future of cardiac care.” To view…

Continue Reading

FridayNov 07, 2025 3:29 pm

BioMedNewsBreaks — Oncotelic Therapeutics Inc. (OTLC) Venture Begins Clinical Trials of Innovative Cancer Therapy

Oncotelic Therapeutics (OTCQB: OTLC) venture Sapu Nano recently secured approval from Australia’s Human Research Ethics Committee (“HREC”) to begin enrolling patients in clinical trials for Sapu003, an injectible form of Afinitor(R) (everolimus) for breast cancer treatment. Using Sapu Nano’s proprietary Deciparticle(TM) technology, Sapu003 delivers Everolimus directly into the bloodstream. “The approval of Sapu003 to enter human trials is a landmark moment. By enabling full drug absorption through intravenous delivery, this program has the potential to achieve meaningful tumor shrinkage where oral formulations have been limited,” said Dr. Sud Agarwal, CEO of Ingenu, a contract research organization in Australia. “We are proud…

Continue Reading

FridayOct 17, 2025 2:54 pm

BioMedNewsBreaks — Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Unveils IzoView: A Game-Changing Platform for Next-Gen Breast Cancer Detection

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) is leading a transformation in breast cancer screening with its flagship IzoView Breast CT Imaging System, a next-generation technology designed to overcome the long-standing limitations of traditional mammography. Unlike compression-based 2D imaging, IzoView delivers true 360-degree, 3D visualization without discomfort, enabling clearer detection—especially in dense breast tissue, which often obscures lesions in standard scans. With a rapid 10-second scan time, high spatial resolution surpassing MRI, and radiation levels comparable to conventional mammography, the system streamlines diagnosis while enhancing patient safety and experience. Built as a scalable platform, IzoView supports future software-driven clinical applications—from screening…

Continue Reading

FridayOct 17, 2025 2:21 pm

BioMedNewsBreaks — Oncotelic Therapeutics Inc. (OTLC) Positioned to Fill Critical Gaps in Cancer Care with RNA and Small-Molecule Therapies

Oncotelic Therapeutics (OTCQB: OTLC) was featured in a recent article that discussed its efforts to pioneer RNA candidates and strategic programs aimed at some of the most lethal and overlooked cancers. “Immunotherapy and RNA-based approaches have begun to reshape the understanding of cancer treatment. The FDA approved 17 new immunotherapies in 2024 alone, spanning multiple cancer types and delivering breakthroughs such as checkpoint inhibitors and individualized vaccines. Yet despite this progress, significant unmet needs persist, particularly in rare pediatric cancers, resistant solid tumors and underserved population. Oncotelic is strategically positioned to fill gaps where traditional treatments fall short,” the article reads.…

Continue Reading